当前位置：
X-MOL 学术
›
Eur. J. Heart Fail.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: A propensity-weighted study
European Journal of Heart Failure ( IF 18.2 ) Pub Date : 2024-04-17 , DOI: 10.1002/ejhf.3220 Alida Linda Patrizia Caforio 1 , Andrea Silvio Giordani 1 , Anna Baritussio 1 , Davide Marcolongo 1 , Cristina Vicenzetto 1 , Giuseppe Tarantini 1 , Massimo Napodano 1 , Giuseppe Toscano 2 , Dario Gregori 3 , Gloria Brigiari 3 , Patrizia Bartolotta 3 , Elisa Carturan 4 , Monica De Gaspari 4 , Stefania Rizzo 4 , Cristina Basso 4 , Sabino Iliceto 1 , Renzo Marcolongo 1
European Journal of Heart Failure ( IF 18.2 ) Pub Date : 2024-04-17 , DOI: 10.1002/ejhf.3220 Alida Linda Patrizia Caforio 1 , Andrea Silvio Giordani 1 , Anna Baritussio 1 , Davide Marcolongo 1 , Cristina Vicenzetto 1 , Giuseppe Tarantini 1 , Massimo Napodano 1 , Giuseppe Toscano 2 , Dario Gregori 3 , Gloria Brigiari 3 , Patrizia Bartolotta 3 , Elisa Carturan 4 , Monica De Gaspari 4 , Stefania Rizzo 4 , Cristina Basso 4 , Sabino Iliceto 1 , Renzo Marcolongo 1
Affiliation
|
Standardized immunosuppressive therapy (IS) had been previously investigated in biopsy-proven (BP) lymphocytic myocarditis with heart failure (HF). This study evaluated efficacy and safety of tailored IS in BP immune-mediated myocarditis, irrespective of histology and clinical presentation.
中文翻译：
定制免疫抑制治疗对免疫介导活检证实的心肌炎的长期疗效和安全性：一项倾向加权研究
标准化免疫抑制治疗（IS）先前已在活检证实（BP）的淋巴细胞性心肌炎伴心力衰竭（HF）中进行过研究。本研究评估了定制 IS 在 BP 免疫介导的心肌炎中的疗效和安全性，无论组织学和临床表现如何。
更新日期：2024-04-17
中文翻译：
定制免疫抑制治疗对免疫介导活检证实的心肌炎的长期疗效和安全性：一项倾向加权研究
标准化免疫抑制治疗（IS）先前已在活检证实（BP）的淋巴细胞性心肌炎伴心力衰竭（HF）中进行过研究。本研究评估了定制 IS 在 BP 免疫介导的心肌炎中的疗效和安全性，无论组织学和临床表现如何。
京公网安备 11010802027423号